TCG Lifesciences has filed its DRHP with SEBI on 1st October 2007 to issue 95 lakh equity shares of Rs 10 each at a price to be decided through 100 per cent book-building process. It is also considering a pre-IPO placement of up to 15 lakh shares with certain investors.
The issue will constitute 14.41% of the fully diluted post issue paid-up capital of the company. The net issue will constitute 13.65% of the fully diluted post Issue paid-up capital of the company.
TCG Lifesciences offers solutions in discovery research, translational research, clinical development and enterprise informatics to the global life sciences industry. The IPO is being made to fund its capital expenditure, finance capital investments in subsidiaries, and repay debt.
The company has been promoted by Dr Purnendu Chatterjee and TCG Lifesciences Mauritius with operations in India, the UK and US, its facilities are located at Kolkata, Mumbai, New Delhi, Pune, New Jersey and High Wycombe.
The BRLMs to the issue are Kotak Mahindra Capital and Enam Securities. The stock is proposed to be listed on the BSE and NSE.